nodes	percent_of_prediction	percent_of_DWPC	metapath
Cabazitaxel—TUBA4A—Vincristine—lymphatic system cancer	0.152	0.174	CbGbCtD
Cabazitaxel—TUBB8—Vincristine—lymphatic system cancer	0.0694	0.0794	CbGbCtD
Cabazitaxel—TUBB2B—Vincristine—lymphatic system cancer	0.0694	0.0794	CbGbCtD
Cabazitaxel—TUBB2A—Vincristine—lymphatic system cancer	0.0694	0.0794	CbGbCtD
Cabazitaxel—TUBB4A—Vincristine—lymphatic system cancer	0.0694	0.0794	CbGbCtD
Cabazitaxel—TUBB3—Vincristine—lymphatic system cancer	0.0694	0.0794	CbGbCtD
Cabazitaxel—TUBB6—Vincristine—lymphatic system cancer	0.0694	0.0794	CbGbCtD
Cabazitaxel—TUBB—Vincristine—lymphatic system cancer	0.0581	0.0664	CbGbCtD
Cabazitaxel—TUBB1—Vincristine—lymphatic system cancer	0.0581	0.0664	CbGbCtD
Cabazitaxel—TUBB4B—Vincristine—lymphatic system cancer	0.0581	0.0664	CbGbCtD
Cabazitaxel—ABCG2—Teniposide—lymphatic system cancer	0.0238	0.0272	CbGbCtD
Cabazitaxel—ABCG2—Mitoxantrone—lymphatic system cancer	0.0167	0.0191	CbGbCtD
Cabazitaxel—SLCO1B3—Methotrexate—lymphatic system cancer	0.015	0.0172	CbGbCtD
Cabazitaxel—CYP3A5—Teniposide—lymphatic system cancer	0.0132	0.0151	CbGbCtD
Cabazitaxel—ABCG2—Vincristine—lymphatic system cancer	0.0115	0.0131	CbGbCtD
Cabazitaxel—SLCO1B1—Methotrexate—lymphatic system cancer	0.00873	0.00999	CbGbCtD
Cabazitaxel—ABCG2—Methotrexate—lymphatic system cancer	0.00694	0.00794	CbGbCtD
Cabazitaxel—CYP3A5—Vincristine—lymphatic system cancer	0.00635	0.00727	CbGbCtD
Cabazitaxel—ABCB1—Mitoxantrone—lymphatic system cancer	0.006	0.00687	CbGbCtD
Cabazitaxel—CYP3A4—Cytarabine—lymphatic system cancer	0.00522	0.00598	CbGbCtD
Cabazitaxel—CYP3A4—Teniposide—lymphatic system cancer	0.00514	0.00589	CbGbCtD
Cabazitaxel—ABCB1—Vincristine—lymphatic system cancer	0.00413	0.00473	CbGbCtD
Cabazitaxel—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0036	0.00412	CbGbCtD
Cabazitaxel—ABCB1—Methotrexate—lymphatic system cancer	0.0025	0.00286	CbGbCtD
Cabazitaxel—CYP3A4—Vincristine—lymphatic system cancer	0.00248	0.00283	CbGbCtD
Cabazitaxel—TUBB6—Zalcitabine—Cytarabine—lymphatic system cancer	0.00126	0.403	CbGdCrCtD
Cabazitaxel—TUBB—Azacitidine—Fludarabine—lymphatic system cancer	0.00068	0.217	CbGdCrCtD
Cabazitaxel—TUBB—Azacitidine—Cytarabine—lymphatic system cancer	0.000642	0.205	CbGdCrCtD
Cabazitaxel—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000298	0.00242	CcSEcCtD
Cabazitaxel—Chills—Bleomycin—lymphatic system cancer	0.000296	0.00241	CcSEcCtD
Cabazitaxel—Renal failure—Mitoxantrone—lymphatic system cancer	0.000293	0.00239	CcSEcCtD
Cabazitaxel—Nausea—Mechlorethamine—lymphatic system cancer	0.000293	0.00239	CcSEcCtD
Cabazitaxel—Alopecia—Bleomycin—lymphatic system cancer	0.000292	0.00237	CcSEcCtD
Cabazitaxel—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000291	0.00237	CcSEcCtD
Cabazitaxel—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00029	0.00236	CcSEcCtD
Cabazitaxel—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00029	0.00236	CcSEcCtD
Cabazitaxel—Abdominal pain—Teniposide—lymphatic system cancer	0.000288	0.00234	CcSEcCtD
Cabazitaxel—Body temperature increased—Teniposide—lymphatic system cancer	0.000288	0.00234	CcSEcCtD
Cabazitaxel—Erythema—Bleomycin—lymphatic system cancer	0.000287	0.00234	CcSEcCtD
Cabazitaxel—Paraesthesia—Fludarabine—lymphatic system cancer	0.000287	0.00234	CcSEcCtD
Cabazitaxel—Hypoaesthesia—Carmustine—lymphatic system cancer	0.000287	0.00233	CcSEcCtD
Cabazitaxel—Dyspnoea—Fludarabine—lymphatic system cancer	0.000285	0.00232	CcSEcCtD
Cabazitaxel—Haematuria—Mitoxantrone—lymphatic system cancer	0.000284	0.00231	CcSEcCtD
Cabazitaxel—Oedema peripheral—Carmustine—lymphatic system cancer	0.000284	0.00231	CcSEcCtD
Cabazitaxel—Connective tissue disorder—Carmustine—lymphatic system cancer	0.000283	0.0023	CcSEcCtD
Cabazitaxel—Dyspepsia—Fludarabine—lymphatic system cancer	0.000282	0.00229	CcSEcCtD
Cabazitaxel—TUBB6—Azacitidine—Fludarabine—lymphatic system cancer	0.000281	0.0897	CbGdCrCtD
Cabazitaxel—Decreased appetite—Fludarabine—lymphatic system cancer	0.000278	0.00226	CcSEcCtD
Cabazitaxel—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000276	0.00225	CcSEcCtD
Cabazitaxel—Fatigue—Fludarabine—lymphatic system cancer	0.000276	0.00224	CcSEcCtD
Cabazitaxel—Hypoaesthesia—Vincristine—lymphatic system cancer	0.000274	0.00223	CcSEcCtD
Cabazitaxel—Pain—Fludarabine—lymphatic system cancer	0.000273	0.00223	CcSEcCtD
Cabazitaxel—Constipation—Fludarabine—lymphatic system cancer	0.000273	0.00223	CcSEcCtD
Cabazitaxel—Urinary tract disorder—Vincristine—lymphatic system cancer	0.000272	0.00221	CcSEcCtD
Cabazitaxel—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00027	0.0022	CcSEcCtD
Cabazitaxel—Urethral disorder—Vincristine—lymphatic system cancer	0.00027	0.00219	CcSEcCtD
Cabazitaxel—Eye disorder—Carmustine—lymphatic system cancer	0.000269	0.00219	CcSEcCtD
Cabazitaxel—Hypersensitivity—Teniposide—lymphatic system cancer	0.000268	0.00218	CcSEcCtD
Cabazitaxel—Flushing—Carmustine—lymphatic system cancer	0.000267	0.00218	CcSEcCtD
Cabazitaxel—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000267	0.00217	CcSEcCtD
Cabazitaxel—Anaemia—Bleomycin—lymphatic system cancer	0.000266	0.00216	CcSEcCtD
Cabazitaxel—TUBB6—Azacitidine—Cytarabine—lymphatic system cancer	0.000265	0.0847	CbGdCrCtD
Cabazitaxel—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000264	0.00214	CcSEcCtD
Cabazitaxel—Asthenia—Teniposide—lymphatic system cancer	0.000261	0.00212	CcSEcCtD
Cabazitaxel—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.00026	0.00211	CcSEcCtD
Cabazitaxel—Malaise—Bleomycin—lymphatic system cancer	0.000259	0.00211	CcSEcCtD
Cabazitaxel—Arrhythmia—Carmustine—lymphatic system cancer	0.000257	0.00209	CcSEcCtD
Cabazitaxel—Leukopenia—Bleomycin—lymphatic system cancer	0.000257	0.00209	CcSEcCtD
Cabazitaxel—Cystitis—Methotrexate—lymphatic system cancer	0.000257	0.00209	CcSEcCtD
Cabazitaxel—Cardiac disorder—Vincristine—lymphatic system cancer	0.000255	0.00208	CcSEcCtD
Cabazitaxel—Alopecia—Carmustine—lymphatic system cancer	0.000255	0.00207	CcSEcCtD
Cabazitaxel—Body temperature increased—Fludarabine—lymphatic system cancer	0.000253	0.00206	CcSEcCtD
Cabazitaxel—Mental disorder—Carmustine—lymphatic system cancer	0.000252	0.00205	CcSEcCtD
Cabazitaxel—Erythema—Carmustine—lymphatic system cancer	0.000251	0.00204	CcSEcCtD
Cabazitaxel—Malnutrition—Carmustine—lymphatic system cancer	0.000251	0.00204	CcSEcCtD
Cabazitaxel—Cough—Bleomycin—lymphatic system cancer	0.000251	0.00204	CcSEcCtD
Cabazitaxel—Angiopathy—Vincristine—lymphatic system cancer	0.00025	0.00203	CcSEcCtD
Cabazitaxel—Diarrhoea—Teniposide—lymphatic system cancer	0.000249	0.00203	CcSEcCtD
Cabazitaxel—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000248	0.00202	CcSEcCtD
Cabazitaxel—Chest pain—Bleomycin—lymphatic system cancer	0.000245	0.00199	CcSEcCtD
Cabazitaxel—Myalgia—Bleomycin—lymphatic system cancer	0.000245	0.00199	CcSEcCtD
Cabazitaxel—Alopecia—Vincristine—lymphatic system cancer	0.000243	0.00198	CcSEcCtD
Cabazitaxel—Back pain—Carmustine—lymphatic system cancer	0.000243	0.00197	CcSEcCtD
Cabazitaxel—Discomfort—Bleomycin—lymphatic system cancer	0.000242	0.00197	CcSEcCtD
Cabazitaxel—Mental disorder—Vincristine—lymphatic system cancer	0.000241	0.00196	CcSEcCtD
Cabazitaxel—Chills—Mitoxantrone—lymphatic system cancer	0.00024	0.00196	CcSEcCtD
Cabazitaxel—Bladder pain—Methotrexate—lymphatic system cancer	0.00024	0.00195	CcSEcCtD
Cabazitaxel—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000239	0.00195	CcSEcCtD
Cabazitaxel—Alopecia—Mitoxantrone—lymphatic system cancer	0.000237	0.00193	CcSEcCtD
Cabazitaxel—Confusional state—Bleomycin—lymphatic system cancer	0.000236	0.00192	CcSEcCtD
Cabazitaxel—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000236	0.00192	CcSEcCtD
Cabazitaxel—Oedema—Bleomycin—lymphatic system cancer	0.000234	0.00191	CcSEcCtD
Cabazitaxel—Erythema—Mitoxantrone—lymphatic system cancer	0.000233	0.0019	CcSEcCtD
Cabazitaxel—Infection—Bleomycin—lymphatic system cancer	0.000233	0.0019	CcSEcCtD
Cabazitaxel—Anaemia—Carmustine—lymphatic system cancer	0.000232	0.00189	CcSEcCtD
Cabazitaxel—Back pain—Vincristine—lymphatic system cancer	0.000232	0.00188	CcSEcCtD
Cabazitaxel—Vomiting—Teniposide—lymphatic system cancer	0.000231	0.00188	CcSEcCtD
Cabazitaxel—Sepsis—Methotrexate—lymphatic system cancer	0.000231	0.00188	CcSEcCtD
Cabazitaxel—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00023	0.00187	CcSEcCtD
Cabazitaxel—Asthenia—Fludarabine—lymphatic system cancer	0.000229	0.00187	CcSEcCtD
Cabazitaxel—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000228	0.00186	CcSEcCtD
Cabazitaxel—Headache—Teniposide—lymphatic system cancer	0.000228	0.00185	CcSEcCtD
Cabazitaxel—Back pain—Mitoxantrone—lymphatic system cancer	0.000226	0.00183	CcSEcCtD
Cabazitaxel—Leukopenia—Carmustine—lymphatic system cancer	0.000224	0.00183	CcSEcCtD
Cabazitaxel—Anorexia—Bleomycin—lymphatic system cancer	0.000224	0.00182	CcSEcCtD
Cabazitaxel—Anaemia—Vincristine—lymphatic system cancer	0.000221	0.0018	CcSEcCtD
Cabazitaxel—Hypotension—Bleomycin—lymphatic system cancer	0.000219	0.00178	CcSEcCtD
Cabazitaxel—Diarrhoea—Fludarabine—lymphatic system cancer	0.000219	0.00178	CcSEcCtD
Cabazitaxel—Hypertension—Carmustine—lymphatic system cancer	0.000217	0.00176	CcSEcCtD
Cabazitaxel—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000216	0.00176	CcSEcCtD
Cabazitaxel—Nausea—Teniposide—lymphatic system cancer	0.000216	0.00176	CcSEcCtD
Cabazitaxel—Anaemia—Mitoxantrone—lymphatic system cancer	0.000216	0.00175	CcSEcCtD
Cabazitaxel—Vertigo—Vincristine—lymphatic system cancer	0.000215	0.00175	CcSEcCtD
Cabazitaxel—Leukopenia—Vincristine—lymphatic system cancer	0.000214	0.00174	CcSEcCtD
Cabazitaxel—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000214	0.00174	CcSEcCtD
Cabazitaxel—Chest pain—Carmustine—lymphatic system cancer	0.000214	0.00174	CcSEcCtD
Cabazitaxel—Myalgia—Carmustine—lymphatic system cancer	0.000214	0.00174	CcSEcCtD
Cabazitaxel—Anxiety—Carmustine—lymphatic system cancer	0.000213	0.00173	CcSEcCtD
Cabazitaxel—Paraesthesia—Bleomycin—lymphatic system cancer	0.000211	0.00171	CcSEcCtD
Cabazitaxel—Malaise—Mitoxantrone—lymphatic system cancer	0.00021	0.00171	CcSEcCtD
Cabazitaxel—Dyspnoea—Bleomycin—lymphatic system cancer	0.000209	0.0017	CcSEcCtD
Cabazitaxel—Renal failure acute—Methotrexate—lymphatic system cancer	0.000209	0.0017	CcSEcCtD
Cabazitaxel—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000209	0.0017	CcSEcCtD
Cabazitaxel—Hypertension—Vincristine—lymphatic system cancer	0.000207	0.00168	CcSEcCtD
Cabazitaxel—Confusional state—Carmustine—lymphatic system cancer	0.000206	0.00168	CcSEcCtD
Cabazitaxel—Oedema—Carmustine—lymphatic system cancer	0.000205	0.00167	CcSEcCtD
Cabazitaxel—Decreased appetite—Bleomycin—lymphatic system cancer	0.000204	0.00166	CcSEcCtD
Cabazitaxel—Myalgia—Vincristine—lymphatic system cancer	0.000204	0.00166	CcSEcCtD
Cabazitaxel—Cough—Mitoxantrone—lymphatic system cancer	0.000203	0.00166	CcSEcCtD
Cabazitaxel—Infection—Carmustine—lymphatic system cancer	0.000203	0.00165	CcSEcCtD
Cabazitaxel—Vomiting—Fludarabine—lymphatic system cancer	0.000203	0.00165	CcSEcCtD
Cabazitaxel—Hypertension—Mitoxantrone—lymphatic system cancer	0.000201	0.00164	CcSEcCtD
Cabazitaxel—Pain—Bleomycin—lymphatic system cancer	0.000201	0.00163	CcSEcCtD
Cabazitaxel—Thrombocytopenia—Carmustine—lymphatic system cancer	0.0002	0.00163	CcSEcCtD
Cabazitaxel—Headache—Fludarabine—lymphatic system cancer	0.0002	0.00163	CcSEcCtD
Cabazitaxel—Tachycardia—Carmustine—lymphatic system cancer	0.0002	0.00163	CcSEcCtD
Cabazitaxel—Myalgia—Mitoxantrone—lymphatic system cancer	0.000199	0.00161	CcSEcCtD
Cabazitaxel—Chest pain—Mitoxantrone—lymphatic system cancer	0.000199	0.00161	CcSEcCtD
Cabazitaxel—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000199	0.00161	CcSEcCtD
Cabazitaxel—Anxiety—Mitoxantrone—lymphatic system cancer	0.000198	0.00161	CcSEcCtD
Cabazitaxel—Lethargy—Methotrexate—lymphatic system cancer	0.000197	0.0016	CcSEcCtD
Cabazitaxel—Discomfort—Mitoxantrone—lymphatic system cancer	0.000196	0.0016	CcSEcCtD
Cabazitaxel—Oedema—Vincristine—lymphatic system cancer	0.000195	0.00159	CcSEcCtD
Cabazitaxel—Anorexia—Carmustine—lymphatic system cancer	0.000195	0.00159	CcSEcCtD
Cabazitaxel—Infection—Vincristine—lymphatic system cancer	0.000194	0.00158	CcSEcCtD
Cabazitaxel—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000193	0.00157	CcSEcCtD
Cabazitaxel—Confusional state—Mitoxantrone—lymphatic system cancer	0.000192	0.00156	CcSEcCtD
Cabazitaxel—Nervous system disorder—Vincristine—lymphatic system cancer	0.000192	0.00156	CcSEcCtD
Cabazitaxel—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000191	0.00156	CcSEcCtD
Cabazitaxel—Hypotension—Carmustine—lymphatic system cancer	0.000191	0.00156	CcSEcCtD
Cabazitaxel—Oedema—Mitoxantrone—lymphatic system cancer	0.00019	0.00155	CcSEcCtD
Cabazitaxel—Nausea—Fludarabine—lymphatic system cancer	0.00019	0.00155	CcSEcCtD
Cabazitaxel—Infection—Mitoxantrone—lymphatic system cancer	0.000189	0.00154	CcSEcCtD
Cabazitaxel—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000186	0.00152	CcSEcCtD
Cabazitaxel—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000186	0.00152	CcSEcCtD
Cabazitaxel—Anorexia—Vincristine—lymphatic system cancer	0.000186	0.00152	CcSEcCtD
Cabazitaxel—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000186	0.00151	CcSEcCtD
Cabazitaxel—Body temperature increased—Bleomycin—lymphatic system cancer	0.000185	0.00151	CcSEcCtD
Cabazitaxel—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000185	0.0015	CcSEcCtD
Cabazitaxel—Paraesthesia—Carmustine—lymphatic system cancer	0.000184	0.0015	CcSEcCtD
Cabazitaxel—Hypotension—Vincristine—lymphatic system cancer	0.000183	0.00149	CcSEcCtD
Cabazitaxel—Dyspnoea—Carmustine—lymphatic system cancer	0.000182	0.00148	CcSEcCtD
Cabazitaxel—Anorexia—Mitoxantrone—lymphatic system cancer	0.000181	0.00148	CcSEcCtD
Cabazitaxel—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000178	0.00145	CcSEcCtD
Cabazitaxel—Decreased appetite—Carmustine—lymphatic system cancer	0.000178	0.00145	CcSEcCtD
Cabazitaxel—Hypotension—Mitoxantrone—lymphatic system cancer	0.000178	0.00145	CcSEcCtD
Cabazitaxel—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000177	0.00144	CcSEcCtD
Cabazitaxel—Paraesthesia—Vincristine—lymphatic system cancer	0.000175	0.00143	CcSEcCtD
Cabazitaxel—Pain—Carmustine—lymphatic system cancer	0.000175	0.00142	CcSEcCtD
Cabazitaxel—Constipation—Carmustine—lymphatic system cancer	0.000175	0.00142	CcSEcCtD
Cabazitaxel—Breast disorder—Methotrexate—lymphatic system cancer	0.000174	0.00142	CcSEcCtD
Cabazitaxel—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000173	0.00141	CcSEcCtD
Cabazitaxel—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000173	0.00141	CcSEcCtD
Cabazitaxel—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000171	0.00139	CcSEcCtD
Cabazitaxel—Decreased appetite—Vincristine—lymphatic system cancer	0.00017	0.00138	CcSEcCtD
Cabazitaxel—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00017	0.00138	CcSEcCtD
Cabazitaxel—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000169	0.00137	CcSEcCtD
Cabazitaxel—Feeling abnormal—Carmustine—lymphatic system cancer	0.000169	0.00137	CcSEcCtD
Cabazitaxel—Fatigue—Vincristine—lymphatic system cancer	0.000168	0.00137	CcSEcCtD
Cabazitaxel—Asthenia—Bleomycin—lymphatic system cancer	0.000168	0.00137	CcSEcCtD
Cabazitaxel—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000168	0.00136	CcSEcCtD
Cabazitaxel—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000167	0.00136	CcSEcCtD
Cabazitaxel—Pain—Vincristine—lymphatic system cancer	0.000167	0.00136	CcSEcCtD
Cabazitaxel—Constipation—Vincristine—lymphatic system cancer	0.000167	0.00136	CcSEcCtD
Cabazitaxel—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000165	0.00135	CcSEcCtD
Cabazitaxel—Fatigue—Mitoxantrone—lymphatic system cancer	0.000164	0.00133	CcSEcCtD
Cabazitaxel—Pain—Mitoxantrone—lymphatic system cancer	0.000163	0.00132	CcSEcCtD
Cabazitaxel—Constipation—Mitoxantrone—lymphatic system cancer	0.000163	0.00132	CcSEcCtD
Cabazitaxel—Abdominal pain—Carmustine—lymphatic system cancer	0.000162	0.00132	CcSEcCtD
Cabazitaxel—Body temperature increased—Carmustine—lymphatic system cancer	0.000162	0.00132	CcSEcCtD
Cabazitaxel—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00016	0.0013	CcSEcCtD
Cabazitaxel—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000157	0.00128	CcSEcCtD
Cabazitaxel—Dysuria—Methotrexate—lymphatic system cancer	0.000156	0.00127	CcSEcCtD
Cabazitaxel—Neutropenia—Methotrexate—lymphatic system cancer	0.000156	0.00127	CcSEcCtD
Cabazitaxel—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000156	0.00127	CcSEcCtD
Cabazitaxel—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000155	0.00126	CcSEcCtD
Cabazitaxel—Abdominal pain—Vincristine—lymphatic system cancer	0.000154	0.00126	CcSEcCtD
Cabazitaxel—Body temperature increased—Vincristine—lymphatic system cancer	0.000154	0.00126	CcSEcCtD
Cabazitaxel—Hypersensitivity—Carmustine—lymphatic system cancer	0.000151	0.00123	CcSEcCtD
Cabazitaxel—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00015	0.00122	CcSEcCtD
Cabazitaxel—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00015	0.00122	CcSEcCtD
Cabazitaxel—Pneumonia—Methotrexate—lymphatic system cancer	0.00015	0.00122	CcSEcCtD
Cabazitaxel—Vomiting—Bleomycin—lymphatic system cancer	0.000149	0.00121	CcSEcCtD
Cabazitaxel—Infestation NOS—Methotrexate—lymphatic system cancer	0.000149	0.00121	CcSEcCtD
Cabazitaxel—Infestation—Methotrexate—lymphatic system cancer	0.000149	0.00121	CcSEcCtD
Cabazitaxel—Asthenia—Carmustine—lymphatic system cancer	0.000147	0.00119	CcSEcCtD
Cabazitaxel—Renal failure—Methotrexate—lymphatic system cancer	0.000146	0.00119	CcSEcCtD
Cabazitaxel—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000144	0.00118	CcSEcCtD
Cabazitaxel—Hypersensitivity—Vincristine—lymphatic system cancer	0.000144	0.00117	CcSEcCtD
Cabazitaxel—Haematuria—Methotrexate—lymphatic system cancer	0.000142	0.00115	CcSEcCtD
Cabazitaxel—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00014	0.00114	CcSEcCtD
Cabazitaxel—Asthenia—Vincristine—lymphatic system cancer	0.00014	0.00114	CcSEcCtD
Cabazitaxel—Diarrhoea—Carmustine—lymphatic system cancer	0.00014	0.00114	CcSEcCtD
Cabazitaxel—Nausea—Bleomycin—lymphatic system cancer	0.000139	0.00113	CcSEcCtD
Cabazitaxel—Asthenia—Mitoxantrone—lymphatic system cancer	0.000137	0.00111	CcSEcCtD
Cabazitaxel—Dizziness—Carmustine—lymphatic system cancer	0.000135	0.0011	CcSEcCtD
Cabazitaxel—Diarrhoea—Vincristine—lymphatic system cancer	0.000134	0.00109	CcSEcCtD
Cabazitaxel—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000132	0.00107	CcSEcCtD
Cabazitaxel—Urethral disorder—Methotrexate—lymphatic system cancer	0.000131	0.00106	CcSEcCtD
Cabazitaxel—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00013	0.00106	CcSEcCtD
Cabazitaxel—Vomiting—Carmustine—lymphatic system cancer	0.00013	0.00106	CcSEcCtD
Cabazitaxel—Dizziness—Vincristine—lymphatic system cancer	0.000129	0.00105	CcSEcCtD
Cabazitaxel—Headache—Carmustine—lymphatic system cancer	0.000128	0.00104	CcSEcCtD
Cabazitaxel—Eye disorder—Methotrexate—lymphatic system cancer	0.000125	0.00101	CcSEcCtD
Cabazitaxel—Tinnitus—Methotrexate—lymphatic system cancer	0.000124	0.00101	CcSEcCtD
Cabazitaxel—Vomiting—Vincristine—lymphatic system cancer	0.000124	0.00101	CcSEcCtD
Cabazitaxel—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000124	0.00101	CcSEcCtD
Cabazitaxel—Headache—Vincristine—lymphatic system cancer	0.000122	0.000996	CcSEcCtD
Cabazitaxel—Nausea—Carmustine—lymphatic system cancer	0.000122	0.000989	CcSEcCtD
Cabazitaxel—Angiopathy—Methotrexate—lymphatic system cancer	0.000121	0.000985	CcSEcCtD
Cabazitaxel—Vomiting—Mitoxantrone—lymphatic system cancer	0.000121	0.000984	CcSEcCtD
Cabazitaxel—Immune system disorder—Methotrexate—lymphatic system cancer	0.000121	0.000981	CcSEcCtD
Cabazitaxel—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00012	0.000978	CcSEcCtD
Cabazitaxel—Chills—Methotrexate—lymphatic system cancer	0.00012	0.000974	CcSEcCtD
Cabazitaxel—Headache—Mitoxantrone—lymphatic system cancer	0.000119	0.00097	CcSEcCtD
Cabazitaxel—Alopecia—Methotrexate—lymphatic system cancer	0.000118	0.000959	CcSEcCtD
Cabazitaxel—Mental disorder—Methotrexate—lymphatic system cancer	0.000117	0.000951	CcSEcCtD
Cabazitaxel—Erythema—Methotrexate—lymphatic system cancer	0.000116	0.000945	CcSEcCtD
Cabazitaxel—Malnutrition—Methotrexate—lymphatic system cancer	0.000116	0.000945	CcSEcCtD
Cabazitaxel—Nausea—Vincristine—lymphatic system cancer	0.000116	0.000944	CcSEcCtD
Cabazitaxel—Dysgeusia—Methotrexate—lymphatic system cancer	0.000114	0.000926	CcSEcCtD
Cabazitaxel—Nausea—Mitoxantrone—lymphatic system cancer	0.000113	0.00092	CcSEcCtD
Cabazitaxel—Back pain—Methotrexate—lymphatic system cancer	0.000112	0.000914	CcSEcCtD
Cabazitaxel—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000108	0.000877	CcSEcCtD
Cabazitaxel—Anaemia—Methotrexate—lymphatic system cancer	0.000107	0.000874	CcSEcCtD
Cabazitaxel—Malaise—Methotrexate—lymphatic system cancer	0.000105	0.000852	CcSEcCtD
Cabazitaxel—Vertigo—Methotrexate—lymphatic system cancer	0.000104	0.000849	CcSEcCtD
Cabazitaxel—Leukopenia—Methotrexate—lymphatic system cancer	0.000104	0.000846	CcSEcCtD
Cabazitaxel—Cough—Methotrexate—lymphatic system cancer	0.000101	0.000825	CcSEcCtD
Cabazitaxel—Arthralgia—Methotrexate—lymphatic system cancer	9.89e-05	0.000805	CcSEcCtD
Cabazitaxel—Myalgia—Methotrexate—lymphatic system cancer	9.89e-05	0.000805	CcSEcCtD
Cabazitaxel—Chest pain—Methotrexate—lymphatic system cancer	9.89e-05	0.000805	CcSEcCtD
Cabazitaxel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	9.82e-05	0.000799	CcSEcCtD
Cabazitaxel—Discomfort—Methotrexate—lymphatic system cancer	9.77e-05	0.000795	CcSEcCtD
Cabazitaxel—Confusional state—Methotrexate—lymphatic system cancer	9.56e-05	0.000778	CcSEcCtD
Cabazitaxel—Infection—Methotrexate—lymphatic system cancer	9.42e-05	0.000766	CcSEcCtD
Cabazitaxel—Nervous system disorder—Methotrexate—lymphatic system cancer	9.3e-05	0.000756	CcSEcCtD
Cabazitaxel—Thrombocytopenia—Methotrexate—lymphatic system cancer	9.28e-05	0.000755	CcSEcCtD
Cabazitaxel—Skin disorder—Methotrexate—lymphatic system cancer	9.21e-05	0.000749	CcSEcCtD
Cabazitaxel—Anorexia—Methotrexate—lymphatic system cancer	9.04e-05	0.000735	CcSEcCtD
Cabazitaxel—Hypotension—Methotrexate—lymphatic system cancer	8.86e-05	0.000721	CcSEcCtD
Cabazitaxel—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	8.64e-05	0.000703	CcSEcCtD
Cabazitaxel—Paraesthesia—Methotrexate—lymphatic system cancer	8.51e-05	0.000693	CcSEcCtD
Cabazitaxel—Dyspnoea—Methotrexate—lymphatic system cancer	8.45e-05	0.000688	CcSEcCtD
Cabazitaxel—Dyspepsia—Methotrexate—lymphatic system cancer	8.35e-05	0.000679	CcSEcCtD
Cabazitaxel—Decreased appetite—Methotrexate—lymphatic system cancer	8.24e-05	0.000671	CcSEcCtD
Cabazitaxel—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	8.19e-05	0.000666	CcSEcCtD
Cabazitaxel—Fatigue—Methotrexate—lymphatic system cancer	8.17e-05	0.000665	CcSEcCtD
Cabazitaxel—Pain—Methotrexate—lymphatic system cancer	8.11e-05	0.00066	CcSEcCtD
Cabazitaxel—Feeling abnormal—Methotrexate—lymphatic system cancer	7.81e-05	0.000636	CcSEcCtD
Cabazitaxel—Gastrointestinal pain—Methotrexate—lymphatic system cancer	7.75e-05	0.000631	CcSEcCtD
Cabazitaxel—Abdominal pain—Methotrexate—lymphatic system cancer	7.49e-05	0.00061	CcSEcCtD
Cabazitaxel—Body temperature increased—Methotrexate—lymphatic system cancer	7.49e-05	0.00061	CcSEcCtD
Cabazitaxel—Hypersensitivity—Methotrexate—lymphatic system cancer	6.99e-05	0.000568	CcSEcCtD
Cabazitaxel—Asthenia—Methotrexate—lymphatic system cancer	6.8e-05	0.000553	CcSEcCtD
Cabazitaxel—Diarrhoea—Methotrexate—lymphatic system cancer	6.49e-05	0.000528	CcSEcCtD
Cabazitaxel—Dizziness—Methotrexate—lymphatic system cancer	6.27e-05	0.00051	CcSEcCtD
Cabazitaxel—Vomiting—Methotrexate—lymphatic system cancer	6.03e-05	0.00049	CcSEcCtD
Cabazitaxel—Headache—Methotrexate—lymphatic system cancer	5.94e-05	0.000483	CcSEcCtD
Cabazitaxel—Nausea—Methotrexate—lymphatic system cancer	5.63e-05	0.000458	CcSEcCtD
